ClinConnect ClinConnect Logo
Search / Trial NCT06043843

Effectiveness of Focused Tele-education in Reducing Diabetes Complications During Ramadan

Launched by SENGKANG GENERAL HOSPITAL · Sep 12, 2023

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying how a special tele-education program can help Muslims with diabetes manage their condition while fasting during Ramadan. The goal is to see if this focused education can reduce serious diabetes complications, such as dangerously low or high blood sugar levels, during this important month. Researchers will involve around 300 adults with type 2 diabetes who plan to fast for at least 15 days. Participants will either receive the new tele-education or continue with their usual diabetes care.

To be eligible for the trial, you need to be at least 21 years old, have type 2 diabetes, and have experience fasting during previous Ramadans. You should also be using insulin for your diabetes management and have access to video conferencing tools, like a smartphone or computer. Throughout the trial, participants will be monitored for any diabetes-related issues, and they will have a follow-up after Ramadan to see how well the program worked. This study aims to help a large number of people maintain better health during Ramadan.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Adults with diabetes planning to fast in Ramadan,
  • 1. Adults with type 2 diabetes aged at least 21 years old,
  • 2. Able to fast at least 15 days in Ramadan based on experience of fasting in previous year's Ramadan,
  • 3. Underlying type 2 diabetes treated with basal insulin and one or more doses of prandial insulin, or at least twice-daily premixed insulin
  • 4. Performed laboratory tests as per standard care - glycated haemoglobin (HbA1c), serum Low Density Lipoprotein- cholesterol, serum triglycerides, serum High Density Lipoprotein- cholesterol, serum Total cholesterol and serum creatinine
  • 5. Ability to give informed consent,
  • 6. Ability to perform self-monitoring blood glucose
  • 7. Have had diabetes-related clinic visits or hospitalization in the past 10 months.
  • 8. Have the capacity for video conferencing (internet connection with mobile phone or computer)
  • Exclusion Criteria:
  • 1. Severe diabetes complications including end-stage renal failure
  • 2. Severe hypoglycemia and hyperglycemic crises within the last 3 months
  • 3. Advanced comorbidities negating the ability to fast
  • 4. Pregnancy
  • 5. Patients on oral medications alone or oral medications plus basal insulin alone
  • 6. Patients on sulfonylureas

About Sengkang General Hospital

Sengkang General Hospital (SKGH) is a leading healthcare institution in Singapore, dedicated to providing comprehensive medical services and advancing clinical research to enhance patient care. As a key player in the region's healthcare landscape, SKGH is committed to fostering innovation through clinical trials that explore new therapies and treatments. The hospital is equipped with state-of-the-art facilities and a multidisciplinary team of experienced healthcare professionals, ensuring a robust environment for conducting high-quality research. By prioritizing ethical standards and patient safety, Sengkang General Hospital aims to contribute significantly to the global medical community and improve health outcomes for diverse populations.

Locations

Singapore, , Singapore

Patients applied

0 patients applied

Trial Officials

Sueziani B Zainudin

Principal Investigator

Sengkang General Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported